While Icure applied for permission for the world's first dementia treatment Donepezil patch, it was found that domestic competitors are still in the Phase I stage.

Icure is expected to preoccupy the domestic market if it obtains a license because it is faster to commercialize than its competitors.

In particular, Donepezil is most often used for the treatment of dementia, and due to the characteristics of dementia patients, it is expected that it will become a competitive drug for the original Aricept because it is a patch formulation that is applied rather than an oral formulation.

On the 13th, Icure and Celltrion announced that they applied for an item license for Donerion